Abraham Abittan, MD
Dermatology · Woodmere, NYNPI 1962548404
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Bristol Myers Squibb at 30.4% of the total. Reporting peaked in 2019 at $7,008 and has fallen 67.8% since, to $2,257 in 2025.
Across 385 payments — averaging $54.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$6K
- Amgen$4K
- Arcutis Biotherapeutics, Inc.$3K
- Johnson & Johnson$2K
- Dermavant Sciences, Inc.$871
- E.r. Squibb & Sons, L.L.C.$820
- plus $4K from 20 others
What the payments were for
- Consulting fees$2,35811%
- Speaking & faculty fees$10,06448%
- Travel & lodging$4002%
- Food & beverage$7,61336%
- Education$4722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 16 | $6,347 |
| Amgen | 7 | $4,434 |
| Arcutis Biotherapeutics, Inc. | 22 | $2,589 |
| Johnson & Johnson | 128 | $1,796 |
| Dermavant Sciences, Inc. | 39 | $871 |
| E.r. Squibb & Sons, L.L.C. | 40 | $820 |
| Novartis | 34 | $588 |
| Pfizer | 22 | $560 |
| Merz North America, Inc. | 2 | $516 |
| AbbVie(2 entities) | 21 | $408 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $363 |
| Regeneron Healthcare Solutions, Inc. | 4 | $363 |
| UCB, Inc. | 17 | $287 |
| Galderma Laboratories, L.p. | 9 | $160 |
| Botanix SB Inc | 3 | $157 |
| Sanofi | 2 | $138 |
| Journey Medical Corporation | 1 | $125 |
| Biofrontera Inc. | 6 | $116 |
| Revance Therapeutics, Inc. | 2 | $104 |
| Smith+Nephew | 1 | $50 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $31 |
| LEO Pharma Inc. | 1 | $19 |
| Almirall LLC | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| EPI Health, LLC | 1 | $16 |
| Prugen, Inc. Pharmaceuticals | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,907 in reported general payments places this provider in the 85th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 24 | $338,705 |
| Dupixent SyringeDupilumab | 27 | $95,501 |
| OtezlaApremilast | 15 | $71,861 |
| Clobetasol Propionate | 121 | $5,845 |
| Ketoconazole | 215 | $4,647 |
| Betamethasone Dipropionate | 61 | $3,654 |
| Alclometasone Dipropionate | 103 | $3,417 |
| Triamcinolone Acetonide | 164 | $2,673 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 34 | $2,561 |
| Mometasone Furoate | 125 | $2,551 |
| Ammonium Lactate | 97 | $2,021 |
| Mupirocin | 244 | $1,893 |
| Clindamycin Phosphate | 38 | $1,653 |
| Betamethasone Valerate | 51 | $1,369 |
| Calcipotriene | 13 | $1,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,796 | $338,70524 claims |
| AmgenOtezla | $4,434 | $71,86115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,151 dermatology providers in New York.
Other dermatology in Woodmere
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.